ADVAXIS INC (ADXS) Stock Price & Overview
NASDAQ:ADXS
The current stock price of ADXS is 0.155 null. Today ADXS is down by -35.42%. In the past month the price decreased by -61.41%. In the past year, price decreased by -59.74%.
ADXS Key Statistics
- Market Cap
- 22.574M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.20
- Dividend Yield
- N/A
ADXS Stock Performance
ADXS Stock Chart
ADXS Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to ADXS. When comparing the yearly performance of all stocks, ADXS is a bad performer in the overall market: 98.63% of all stocks are doing better.
ADXS Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ADXS. ADXS may be in some trouble as it scores bad on both profitability and health.
ADXS Earnings
ADXS Forecast & Estimates
7 analysts have analysed ADXS and the average price target is 2.3 null. This implies a price increase of 1380.65% is expected in the next year compared to the current price of 0.155.
ADXS Groups
Sector & Classification
ADXS Financial Highlights
Over the last trailing twelve months ADXS reported a non-GAAP Earnings per Share(EPS) of -0.2. The EPS increased by 58.75% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -581.85% | ||
| ROA | -37.01% | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
ADXS Ownership
ADXS Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.3 | 402.17B | ||
| AMGN | AMGEN INC | 16.45 | 203.213B | ||
| GILD | GILEAD SCIENCES INC | 16.81 | 182.029B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.75 | 117.075B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.51 | 82.631B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 43.21 | 42.915B | ||
| INSM | INSMED INC | N/A | 30.852B | ||
| NTRA | NATERA INC | N/A | 29.086B | ||
| BIIB | BIOGEN INC | 11.72 | 27.626B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.94 | 23.193B | ||
| MRNA | MODERNA INC | N/A | 22.014B | ||
| EXAS | EXACT SCIENCES CORP | 340.08 | 19.797B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.775B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About ADXS
Company Profile
Advaxis, Inc. is a biotechnology company, which engages in the discovery, development and commercialization of cancer immunotherapies. The company is headquartered in Monmouth Junction, New Jersey and currently employs 18 full-time employees. The company went IPO on 2005-07-28. The firm is using its Lm platform directed against tumor-specific targets to engage the patient's immune system to destroy tumor cells. These immunotherapies are based on a platform technology that utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant fusion proteins. Its Lm platform technology has clinical activity in several programs. These Lm strains integrate multiple functions into a single immunotherapy as they access and direct antigen presenting cells to stimulate anti-tumor T-cell immunity, stimulate and activate the immune system with the equivalent of multiple adjuvants, and simultaneously reduce tumor protection in the tumor microenvironment (TME) to enable the T-cells to eliminate tumors.
Company Info
IPO: 2005-07-28
ADVAXIS INC
9 Deer Park Drive, Suite K-1
Monmouth Junction NEW JERSEY 08540 US
CEO: Kenneth Berlin
Employees: 18
Phone: 17325451590.0
ADVAXIS INC / ADXS FAQ
What does ADXS do?
Advaxis, Inc. is a biotechnology company, which engages in the discovery, development and commercialization of cancer immunotherapies. The company is headquartered in Monmouth Junction, New Jersey and currently employs 18 full-time employees. The company went IPO on 2005-07-28. The firm is using its Lm platform directed against tumor-specific targets to engage the patient's immune system to destroy tumor cells. These immunotherapies are based on a platform technology that utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant fusion proteins. Its Lm platform technology has clinical activity in several programs. These Lm strains integrate multiple functions into a single immunotherapy as they access and direct antigen presenting cells to stimulate anti-tumor T-cell immunity, stimulate and activate the immune system with the equivalent of multiple adjuvants, and simultaneously reduce tumor protection in the tumor microenvironment (TME) to enable the T-cells to eliminate tumors.
Can you provide the latest stock price for ADVAXIS INC?
The current stock price of ADXS is 0.155 null. The price decreased by -35.42% in the last trading session.
What is the dividend status of ADVAXIS INC?
ADXS does not pay a dividend.
What is the ChartMill rating of ADVAXIS INC stock?
ADXS has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
On which exchange is ADXS stock listed?
ADXS stock is listed on the Nasdaq exchange.
Can you provide the PE ratio for ADXS stock?
ADVAXIS INC (ADXS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.2).